Jonathan S Katz, MD
Neurology · Novato
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 8
Offices
8 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Looking this up.
Hospitals listed: 058123 · California Pacific Medical Center - Mission Bernal · California Pacific Medical Center- Van Ness Campus · Sutter Auburn Faith Hospital · Sutter Medical Center, Sacramento. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Katz’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A54410 · Current
Licensed to practise in California · since 1995 · expires 2027-05-31 · Tulane University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
4 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- California Pacific Medical Center - Mission BernalSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Church · Has an emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 76% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.322, Oct 2024 – Sep 2025
- California Pacific Medical Center- Van Ness CampusSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.224, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.325, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.373, Oct 2024 – Sep 2025
- Sutter Auburn Faith HospitalAuburn, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 79% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0, Oct 2024 – Sep 2025
- Sutter Medical Center, SacramentoSacramento, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 79% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 13.9 (12 to 15.9) · 992 cases, Jan 2024 – Dec 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.066, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.335, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.215, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.46, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.253, Oct 2024 – Sep 2025
See every measure and the patient survey for California Pacific Medical Center - Mission Bernal
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 0 better, 3 the same, 3 worse of 6 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.322 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.19 to 2.28) · 336 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.87 (0.47 to 1.27) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 163.19 (101.27 to 225.11) · 28 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.5 · 44 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.6 · 155 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.4 · 177 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.6 · 32 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.2 · 1,281 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.42) · 2,912 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.24 (0.04 to 0.45) · 2,681 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.07 (1.81 to 6.33) · 787 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.61 (0 to 3.31) · 425 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.46 (0.79 to 4.12) · 755 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.36 (0 to 16.38) · 431 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.47 (1.38 to 9.55) · 401 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.7 (0.2 to 3.2) · 105 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 1.16) · 2,291 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 2.4 · 369 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.602 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.618 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22 · 242 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 20.9 · 197 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 39.6 · 203 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 292 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.9 · 353 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.9 · 74 cases | None | Jul 2023 – Jun 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 110 cases | No different | Jan 2024 – Dec 2024 |
What patients said (406 patients answered, 18% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 78% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 78% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 74% |
| Staff "always" explained new medications | 74% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 75% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 76% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
See every measure and the patient survey for California Pacific Medical Center- Van Ness Campus
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 0 better, 8 the same, 2 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.224 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.325 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.373 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.14 (0.3 to 1.97) · 2,271 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.81 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 192.86 (151.51 to 234.22) · 140 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 10.3 · 60 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.5 · 143 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.8 · 356 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.3 · 259 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 173 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.1 · 2,316 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.31 (0.12 to 0.49) · 6,430 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.09 to 0.47) · 7,168 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.3 (1.5 to 5.09) · 2,196 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.47 (1.21 to 3.74) · 925 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.63 (1.37 to 3.88) · 1,954 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.13 (6.06 to 14.2) · 1,112 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.26 (4.67 to 9.85) · 1,084 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.67 (0.31 to 3.03) · 832 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.33 (0 to 0.85) · 5,406 cases | No different | Jul 2022 – Jun 2024 |
| MRSA BacteremiaInfections | 0.443 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.717 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 200 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.3 · 449 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 18.2 · 187 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 8.7 · 418 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 7.1 · 260 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19.2 · 293 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (3.6 to 7.6) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.2 (7.7 to 13.5) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 11 · 33 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.2 · 66 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.5 (9.4 to 16.7) · 551 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.3) · 219 cases | No different | Jan 2024 – Dec 2024 |
What patients said (478 patients answered, 20% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 74% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 70% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for Sutter Auburn Faith Hospital
Behind the star rating — Deaths: 0 better, 6 the same, 0 worse of 6 measures. Safety: 1 better, 4 the same, 0 worse of 5 measures. Readmissions: 3 better, 6 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0 to 2.01) · 312 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.04 (0.62 to 1.46) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 160.66 (100.73 to 220.58) · 26 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 9.5 · 63 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 12.7 · 160 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 16 · 241 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.6 · 105 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.9 · 1,272 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.42) · 2,484 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.29 (0.08 to 0.5) · 2,442 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.11 (1.72 to 6.49) · 442 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.61 (0 to 3.31) · 130 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.12 (0.47 to 3.78) · 417 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.72 (0.67 to 18.77) · 133 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 8.26 (4.11 to 12.4) · 113 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.68 (0.18 to 3.18) · 135 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.33 (0 to 1.3) · 1,845 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.4 · 34 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.2 · 215 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.9 · 178 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -30.1 · 250 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.1 · 300 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.5 (3.5 to 8.5) · 58 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.6 (8 to 16.4) · 58 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 32 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 18.8 · 95 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.7 (9 to 15.2) · 1,787 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.3) · 473 cases | No different | Jan 2024 – Dec 2024 |
What patients said (563 patients answered, 27% of those asked)
| Cleanliness | 5 |
| Nurse communication | 5 |
| Doctor communication | 4 |
| Communication about medicines | 4 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 81% |
| Nurses "always" communicated well | 83% |
| Doctors "always" communicated well | 84% |
| Staff "always" explained | 66% |
| Yes, staff "did" give patients this information | 90% |
| Yes, staff "did" give patients information about help after discharge | 91% |
| Doctors "always" explained things so they could understand | 81% |
| Doctors "always" listened carefully | 82% |
| Doctors "always" treated them with courtesy and respect | 89% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 79% |
| Nurses "always" explained things so they could understand | 80% |
| Nurses "always" listened carefully | 81% |
| Nurses "always" treated them with courtesy and respect | 89% |
| "Always" quiet at night | 51% |
| "YES", patients would definitely recommend the hospital | 79% |
| Staff "always" explained possible side effects | 53% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Sutter Medical Center, Sacramento
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 0 better, 9 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.9 (12 to 15.9) · 992 cases | Worse | Jan 2024 – Dec 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.066 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.335 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.215 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.46 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.253 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.12 (0.29 to 1.94) · 2,408 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.99 (0.78 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.68 (126.66 to 206.71) · 180 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.4 · 292 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.7 · 143 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.2 · 359 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.8 · 543 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.9 · 425 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.4 · 441 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 5,216 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.11 (0 to 0.29) · 9,948 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.1 to 0.45) · 10,968 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.04 (1.53 to 4.56) · 3,983 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.33 (0.2 to 2.46) · 2,033 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.78 (1.69 to 3.87) · 3,594 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.79 (6.29 to 13.29) · 2,100 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.62 (4.04 to 9.2) · 2,018 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.63 (0.29 to 2.98) · 867 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.54 (0.07 to 1.01) · 8,613 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.3 · 294 cases | None | Apr 2023 – Mar 2025 |
| SSI - Abdominal HysterectomyInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 598 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.9 · 924 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 8.5 · 488 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -18.3 · 638 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 24.4 · 443 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.7 · 600 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.9 (3.9 to 6.1) · 992 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 298 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9 · 249 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 250 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.3 (8.7 to 14.6) · 1,326 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.3) · 934 cases | No different | Jan 2024 – Dec 2024 |
What patients said (700 patients answered, 20% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 84% |
| Doctors "always" explained things so they could understand | 75% |
| Doctors "always" listened carefully | 77% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 49% |
| "YES", patients would definitely recommend the hospital | 79% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
Original Medicare doctor bills
$93,175
Medicare paid this office $93,175 for 339 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 149 | $34,431 | $153 |
| New patient visit (60+ min) | 73 | $13,505 | $185 |
| Nerve test | 29 | $7,089 | $244 |
| Return visit (30+ min) | 55 | $6,664 | $109 |
| New patient visit (45+ min) | 32 | $4,743 | $148 |
See all 15 services
| Long return visit (40+ min) | 149 | $34,431 | $153 |
| New patient visit (60+ min) | 73 | $13,505 | $185 |
| Nerve test | 29 | $7,089 | $244 |
| Return visit (30+ min) | 55 | $6,664 | $109 |
| New patient visit (45+ min) | 32 | $4,743 | $148 |
| Muscle electrical test | 42 | $4,544 | $99 |
| Nerve test | 17 | $3,568 | $210 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 22 | $3,179 | $145 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 74 | $1,642 | $14 |
| Treatment of swallowing and feeding disorder | 11 | $1,514 | $72 |
| Nerve test | 14 | $1,485 | $106 |
| New patient visit (30+ min) | 16 | $1,464 | $92 |
| Treatment of speech, language, voice, communication, and/or hearing processing disorder | 11 | $1,239 | $54 |
| Short return visit (20+ min) | 11 | $866 | $79 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 15 | $469 | $29 |
Who their Medicare patients are
339 Original Medicare patients in 2024. Average age 74 · Under 65 12% · 85 and older 11% · Women 45% · Also on Medicaid 27% · Health risk score 1.55. At or below the middle of the specialty; the typical neurology clinician is at 1.61.
Conditions among them: High blood pressure 71% · Diabetes 27% · Coronary heart disease 26% · Depression 26% · Chronic kidney disease 24% · Atrial fibrillation 22% · Heart failure 14% · Cancer 14% · Stroke 13% · COPD 11% · Dementia 11%.
The office billed $448,030, Medicare allowed $125,593 and paid $93,175; for 785 services of 28 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 339 | 785 | 74 | 1.55 | $448,030 | $93,175 |
| 2023 | 290 | 631 | 73 | 1.68 | $345,953 | $85,438 |
| 2022 | 258 | 563 | 72 | 1.70 | $294,491 | $73,343 |
| 2021 | 291 | 670 | 72 | 1.57 | $320,426 | $82,607 |
| 2020 | 255 | 600 | 72 | 1.52 | $313,714 | $71,013 |
| 2019 | 284 | 629 | 71 | 1.51 | $321,564 | $69,196 |
| 2018 | 218 | 535 | 69 | 1.63 | $251,528 | $52,240 |
| 2017 | 294 | 754 | 70 | 1.58 | $353,963 | $78,219 |
| 2016 | 316 | 908 | 68 | 1.56 | $351,038 | $77,892 |
| 2015 | 328 | 1,027 | 70 | 1.55 | $384,640 | $84,747 |
| 2014 | 304 | 1,003 | 69 | 1.51 | $387,038 | $81,943 |
| 2013 | 280 | 888 | 69 | 1.76 | $336,655 | $69,080 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 11 services
| Long return visit (40+ min) | 138 | $36,470 | $155 |
| New patient visit (60+ min) | 61 | $12,283 | $201 |
| Return visit (30+ min) | 51 | $6,577 | $113 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 39 | $5,942 | $149 |
| New patient visit (45+ min) | 19 | $3,005 | $158 |
| Nerve test | 11 | $2,728 | $248 |
| Evaluation for physical therapy, typically 20 minutes | 21 | $2,552 | $95 |
| Muscle electrical test | 20 | $2,320 | $101 |
| Evaluation for occupational therapy, typically 30 minutes | 17 | $2,056 | $86 |
| Short return visit (20+ min) | 12 | $1,135 | $87 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 20 | $610 | $29 |
2022: 10 services
| Long return visit (40+ min) | 103 | $27,007 | $151 |
| New patient visit (60+ min) | 58 | $10,885 | $188 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 46 | $8,661 | $177 |
| Return visit (30+ min) | 34 | $4,219 | $103 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 13 | $2,829 | $91 |
| Muscle electrical test | 18 | $2,461 | $103 |
| Evaluation for physical therapy, typically 20 minutes | 21 | $2,207 | $85 |
| Evaluation for occupational therapy, typically 30 minutes | 20 | $1,982 | $86 |
| Treatment of speech, language, voice, communication, and/or hearing processing disorder | 11 | $701 | $54 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 11 | $441 | $29 |
2021: 15 services
| Long return visit (40+ min) | 105 | $27,225 | $151 |
| Return visit (30+ min) | 50 | $8,698 | $116 |
| New patient visit (60+ min) | 46 | $8,207 | $178 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 40 | $7,209 | $180 |
| Evaluation for physical therapy, typically 20 minutes | 38 | $4,228 | $94 |
| Evaluation for occupational therapy, typically 30 minutes | 26 | $2,420 | $81 |
| New patient visit (45+ min) | 19 | $2,414 | $127 |
| Long return visit (40+ min) | 15 | $2,403 | $114 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 19 | $2,260 | $119 |
| Muscle electrical test | 16 | $2,101 | $105 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 14 | $1,984 | $94 |
| New patient visit (60+ min) | 11 | $1,627 | $148 |
| Treatment of speech, language, voice, communication, and/or hearing processing disorder | 17 | $1,236 | $59 |
| Treatment of swallowing and feeding disorder | 12 | $924 | $66 |
| Short return visit (20+ min) | 11 | $801 | $67 |
2020: 9 services
| Long return visit (40+ min) | 95 | $22,276 | $123 |
| New patient visit (60+ min) | 50 | $9,169 | $183 |
| Return visit (30+ min) | 44 | $7,679 | $101 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 33 | $6,183 | $182 |
| Long return visit (40+ min) | 32 | $3,951 | $96 |
| Evaluation for physical therapy, typically 20 minutes | 29 | $2,828 | $79 |
| New patient visit (60+ min) | 18 | $2,745 | $153 |
| Muscle electrical test | 17 | $2,281 | $99 |
| Evaluation for occupational therapy, typically 30 minutes | 17 | $1,441 | $85 |
2019: 14 services
| Long return visit (40+ min) | 114 | $22,659 | $121 |
| New patient visit (60+ min) | 52 | $9,037 | $174 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 32 | $5,835 | $182 |
| Return visit (30+ min) | 48 | $5,378 | $85 |
| Treatment of swallowing and feeding disorder | 26 | $2,303 | $68 |
| Treatment of speech, language, voice, communication, and/or hearing processing disorder | 25 | $1,964 | $55 |
| Evaluation for occupational therapy, typically 30 minutes | 22 | $1,837 | $83 |
| New patient visit (60+ min) | 12 | $1,816 | $151 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 13 | $1,687 | $94 |
| Long return visit (40+ min) | 14 | $1,605 | $100 |
| Muscle electrical test | 13 | $1,330 | $95 |
| Evaluation for physical therapy, typically 20 minutes | 17 | $1,304 | $72 |
| Return visit (30+ min) | 13 | $927 | $71 |
| Short return visit (20+ min) | 12 | $851 | $61 |
2018: 11 services
| Long return visit (40+ min) | 80 | $14,270 | $111 |
| New patient visit (60+ min) | 44 | $7,584 | $172 |
| Return visit (30+ min) | 46 | $4,742 | $83 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 18 | $2,810 | $156 |
| Short return visit (20+ min) | 35 | $2,714 | $63 |
| Treatment of swallowing and feeding disorder | 22 | $2,258 | $71 |
| Treatment of speech, language, voice, communication, and/or hearing processing disorder | 24 | $1,946 | $56 |
| Muscle electrical test | 17 | $1,845 | $88 |
| New patient visit (30+ min) | 15 | $1,503 | $100 |
| Evaluation for occupational therapy, typically 30 minutes | 15 | $1,321 | $83 |
| Short return visit | 17 | $722 | $38 |
2017: 13 services
| Long return visit (40+ min) | 141 | $26,515 | $119 |
| New patient visit (60+ min) | 83 | $15,157 | $183 |
| Return visit (30+ min) | 36 | $4,355 | $84 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 24 | $4,265 | $178 |
| Treatment of swallowing and feeding disorder | 27 | $2,720 | $72 |
| Evaluation for occupational therapy, typically 30 minutes | 28 | $2,675 | $81 |
| Treatment of speech, language, voice, communication, and/or hearing processing disorder | 34 | $2,566 | $57 |
| Muscle electrical test | 21 | $2,401 | $89 |
| Nerve test | 12 | $2,338 | $195 |
| New patient visit (45+ min) | 12 | $1,568 | $131 |
| New patient visit (60+ min) | 12 | $1,370 | $114 |
| Therapy procedure using functional activities | 22 | $854 | $24 |
| Short return visit (20+ min) | 14 | $692 | $49 |
2016: 15 services
| Long return visit (40+ min) | 144 | $26,541 | $111 |
| New patient visit (60+ min) | 63 | $11,129 | $177 |
| Return visit (30+ min) | 47 | $6,534 | $96 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 22 | $3,908 | $178 |
| New patient visit (45+ min) | 19 | $2,405 | $127 |
| Treatment of speech, language, voice, communication, and/or hearing processing disorder | 27 | $2,194 | $59 |
| Treatment of swallowing and feeding disorder | 23 | $2,142 | $71 |
| Physical therapy evaluation | 29 | $1,966 | $60 |
| New patient visit (60+ min) | 11 | $1,658 | $151 |
| Occupational therapy evaluation | 18 | $1,606 | $80 |
| Test to measure expiratory airflow and volume | 26 | $1,397 | $33 |
| Therapeutic procedures to increase strength or endurance of respiratory muscles, face to face, one on one, each 15 minutes (includes monitoring) | 44 | $1,244 | $10 |
| New patient visit (45+ min) | 11 | $1,130 | $103 |
| Short return visit (20+ min) | 13 | $836 | $64 |
| Therapy procedure using functional activities | 22 | $673 | $24 |
2015: 17 services
| Long return visit (40+ min) | 152 | $28,546 | $116 |
| New patient visit (60+ min) | 62 | $11,078 | $179 |
| Return visit (30+ min) | 52 | $6,246 | $89 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 30 | $5,719 | $179 |
| Treatment of swallowing and feeding disorder | 28 | $2,769 | $77 |
| Muscle electrical test | 25 | $2,662 | $92 |
| New patient visit (45+ min) | 20 | $2,591 | $130 |
| Nerve test | 16 | $2,367 | $148 |
| Treatment of speech, language, voice, communication, and/or hearing processing disorder | 28 | $2,147 | $61 |
| Therapy procedure using functional activities | 42 | $1,800 | $26 |
| New patient visit (45+ min) | 14 | $1,519 | $109 |
| Therapeutic procedures to increase strength or endurance of respiratory muscles, face to face, one on one, each 15 minutes (includes monitoring) | 48 | $1,432 | $10 |
| Test to measure expiratory airflow and volume | 34 | $1,373 | $34 |
| Training for self-care or home management, each 15 minutes | 23 | $853 | $26 |
| Therapy procedure using exercise to develop strength, endurance, range of motion, and flexibility, each 15 minutes | 31 | $848 | $22 |
| Short return visit (20+ min) | 13 | $706 | $54 |
| Evaluation for wheelchair, each 15 minutes | 12 | $249 | $21 |
2014: 19 services
| Long return visit (40+ min) | 145 | $26,406 | $117 |
| New patient visit (60+ min) | 74 | $13,002 | $176 |
| Return visit (30+ min) | 46 | $5,562 | $96 |
| New patient visit (60+ min) | 19 | $2,840 | $149 |
| New patient visit (45+ min) | 17 | $2,442 | $144 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 12 | $2,168 | $181 |
| Treatment of speech, language, voice, communication, and/or hearing processing disorder | 23 | $2,004 | $61 |
| Muscle electrical test | 18 | $2,002 | $91 |
| Test to measure expiratory airflow and volume | 44 | $1,873 | $34 |
| Treatment of swallowing and feeding disorder | 17 | $1,776 | $74 |
| Therapeutic procedures to increase strength or endurance of respiratory muscles, face to face, one on one, each 15 minutes (includes monitoring) | 53 | $1,358 | $10 |
| Training for self-care or home management, each 15 minutes | 34 | $1,293 | $26 |
| New patient visit (45+ min) | 11 | $1,278 | $116 |
| Therapy procedure using exercise to develop strength, endurance, range of motion, and flexibility, each 15 minutes | 42 | $1,175 | $23 |
| Nerve test | 12 | $1,113 | $93 |
| Short return visit (20+ min) | 17 | $1,046 | $58 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 11 | $1,021 | $93 |
| Therapy procedure using functional activities | 12 | $387 | $28 |
| Evaluation for wheelchair, each 15 minutes | 12 | $318 | $20 |
2013: 16 services
| Long return visit (40+ min) | 124 | $23,559 | $118 |
| New patient visit (60+ min) | 47 | $8,212 | $175 |
| Return visit (30+ min) | 48 | $5,581 | $90 |
| New patient visit (45+ min) | 26 | $3,849 | $148 |
| Muscle electrical test | 24 | $2,545 | $85 |
| Training for self-care or home management, each 15 minutes | 37 | $1,905 | $28 |
| Nerve test | 14 | $1,900 | $136 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 16 | $1,524 | $90 |
| Therapeutic procedures to increase strength or endurance of respiratory muscles, face to face, one on one, each 15 minutes (includes monitoring) | 37 | $1,523 | $11 |
| Treatment of speech, language, voice, communication, and/or hearing processing disorder | 21 | $1,373 | $57 |
| Short return visit (20+ min) | 15 | $1,309 | $69 |
| Treatment of swallowing and feeding disorder | 15 | $1,225 | $68 |
| Test to measure expiratory airflow and volume | 20 | $1,047 | $37 |
| Training in the use of orthopedic device for arm, leg and/or trunk, each 15 minutes | 18 | $708 | $32 |
| Evaluation for wheelchair, each 15 minutes | 15 | $614 | $25 |
| Therapy procedure using exercise to develop strength, endurance, range of motion, and flexibility, each 15 minutes | 20 | $599 | $24 |
Drugs they prescribed that Part D paid
$6,437,820
Pharmacies billed $6,437,820 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 1% of their Part D prescriptions (11 of 1,114) in 2024. Above the middle of the specialty; the typical neurology clinician is at 0%.
701 generic and fewer than 11 brand-name prescriptions · $6,437,820 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Radicava Ors | None | 150 | $2,101,781 | $14,012 |
| Acthar | None | 12 | $903,502 | $75,292 |
| Evrysdi | None | 25 | $788,937 | $31,557 |
| Gamunex-C | Immune globulin | 57 | $615,297 | $10,795 |
| Privigen | Immune globulin | 31 | $554,776 | $17,896 |
See all 25 drugs
| Radicava Ors | None | 150 | $2,101,781 | $14,012 |
| Acthar | None | 12 | $903,502 | $75,292 |
| Evrysdi | None | 25 | $788,937 | $31,557 |
| Gamunex-C | Immune globulin | 57 | $615,297 | $10,795 |
| Privigen | Immune globulin | 31 | $554,776 | $17,896 |
| Gammaplex | Immune globulin | 68 | $471,257 | $6,930 |
| Relyvrio | None | 24 | $298,638 | $12,443 |
| Octagam | Immune globulin | 16 | $128,105 | $8,007 |
| Riluzole | None | 127 | $23,966 | $189 |
| Azathioprine | None | 43 | $12,763 | $297 |
| Mycophenolate Mofetil | None | 43 | $3,507 | $82 |
| Gabapentin | None | 121 | $1,996 | $16 |
| Atropine Sulfate | None | 14 | $1,499 | $107 |
| Levetiracetam | None | 21 | $1,131 | $54 |
| Pyridostigmine | None | 17 | $1,095 | $64 |
| Prednisone | None | 92 | $634 | $7 |
| Glycopyrrolate | None | 16 | $595 | $37 |
| Hydrocodone-Acetaminophen | None | 11 | $354 | $32 |
| Zolpidem | None | 16 | $264 | $16 |
| Baclofen | None | 16 | $245 | $15 |
| Lacosamide | None | 11 | $196 | $18 |
| Pregabalin | None | 15 | $159 | $11 |
| Alprazolam | None | 16 | $153 | $10 |
| Nortriptyline | None | 19 | $116 | $6 |
| Amitriptyline | None | 13 | $77 | $6 |
Year by year
| 2024 | 1,114 | 133 | 1% (11) | None | $6,437,820 |
| 2023 | 1,158 | 133 | 1% (13) | 37% | $6,721,146 |
| 2022 | 1,049 | 146 | None | 32% | $4,807,850 |
| 2021 | 1,159 | 159 | 2% (25) | 29% | $4,373,635 |
| 2020 | 1,214 | 155 | 4% (42) | 25% | $3,742,714 |
| 2019 | 890 | 132 | 4% (34) | 23% | $2,148,666 |
| 2018 | 825 | 112 | 4% (36) | 24% | $1,966,907 |
| 2017 | 878 | 122 | 6% (49) | 21% | $2,151,552 |
| 2016 | 923 | 126 | 7% (64) | 19% | $1,521,555 |
| 2015 | 844 | 117 | 6% (46) | None | $521,169 |
| 2014 | 773 | 121 | 4% (33) | 14% | $388,804 |
| 2013 | 578 | 91 | 4% (23) | None | $608,416 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 27 drugs
| Radicava Ors | None | 107 | $1,490,478 | $13,930 |
| Relyvrio | None | 84 | $1,040,085 | $12,382 |
| Evrysdi | None | 25 | $754,727 | $30,189 |
| Gamunex-C | Immune globulin | 49 | $587,080 | $11,981 |
| Privigen | Immune globulin | 21 | $487,488 | $23,214 |
| Gammaplex | Immune globulin | 60 | $414,715 | $6,912 |
| Octagam | Immune globulin | 13 | $188,679 | $14,514 |
| Riluzole | None | 129 | $24,191 | $188 |
| Azathioprine | None | 37 | $13,208 | $357 |
| Gabapentin | None | 115 | $4,203 | $37 |
| Mycophenolate Mofetil | None | 24 | $3,740 | $156 |
| Pyridostigmine | None | 17 | $2,862 | $168 |
| Atropine Sulfate | None | 19 | $1,635 | $86 |
| Glycopyrrolate | None | 29 | $1,327 | $46 |
| Prednisone | None | 82 | $1,068 | $13 |
| Baclofen | None | 34 | $801 | $24 |
| Pregabalin | None | 20 | $749 | $37 |
| Levetiracetam | None | 30 | $640 | $21 |
| Amitriptyline | None | 28 | $557 | $20 |
| Sertraline | None | 14 | $380 | $27 |
| Hydrocodone-Acetaminophen | None | 13 | $327 | $25 |
| Lacosamide | None | 12 | $244 | $20 |
| Duloxetine | None | 20 | $226 | $11 |
| Donepezil | None | 12 | $156 | $13 |
| Zolpidem | None | 11 | $118 | $11 |
| Alprazolam | None | 15 | $114 | $8 |
| Sodium Chloride | None | 14 | $91 | $7 |
2022: 30 drugs
| Acthar | None | 12 | $1,163,537 | $96,961 |
| Radicava | None | 86 | $1,059,047 | $12,315 |
| Radicava Ors | None | 40 | $567,571 | $14,189 |
| Gamunex-C | Immune globulin | 34 | $461,553 | $13,575 |
| Evrysdi | None | 12 | $408,859 | $34,072 |
| Privigen | Immune globulin | 13 | $350,240 | $26,942 |
| Gammaplex | Immune globulin | 51 | $247,267 | $4,848 |
| Octagam | Immune globulin | 18 | $217,058 | $12,059 |
| Gammagard Liquid | Immune globulin | 18 | $137,517 | $7,640 |
| Riluzole | None | 142 | $28,205 | $199 |
| Nuedexta | None | 17 | $26,151 | $1,538 |
| Vimpat | None | 13 | $14,702 | $1,131 |
| Atropine Sulfate | None | 23 | $2,169 | $94 |
| Gabapentin | None | 89 | $1,715 | $19 |
| Mycophenolate Mofetil | None | 18 | $1,562 | $87 |
| Pregabalin | None | 14 | $1,144 | $82 |
| Pyridostigmine | None | 15 | $1,054 | $70 |
| Donepezil | None | 68 | $1,023 | $15 |
| Prednisone | None | 84 | $976 | $12 |
| Amitriptyline | None | 30 | $578 | $19 |
| Primidone | None | 19 | $486 | $26 |
| Levetiracetam | None | 12 | $321 | $27 |
| Baclofen | None | 14 | $309 | $22 |
| Sertraline | None | 16 | $294 | $18 |
| Glycopyrrolate | None | 19 | $252 | $13 |
| Lorazepam | None | 14 | $165 | $12 |
| Duloxetine | None | 12 | $145 | $12 |
| Quetiapine | None | 12 | $132 | $11 |
| Zolpidem | None | 11 | $106 | $10 |
| Trazodone | None | 11 | $36 | $3 |
2021: 29 drugs
| Radicava | None | 123 | $1,485,449 | $12,077 |
| Acthar | None | 12 | $1,097,114 | $91,426 |
| Evrysdi | None | 11 | $389,273 | $35,388 |
| Gamunex-C | Immune globulin | 28 | $363,607 | $12,986 |
| Privigen | Immune globulin | 13 | $325,399 | $25,031 |
| Gammaplex | Immune globulin | 51 | $285,903 | $5,606 |
| Gammagard Liquid | Immune globulin | 28 | $273,806 | $9,779 |
| Nuedexta | None | 29 | $46,679 | $1,610 |
| Riluzole | None | 153 | $28,166 | $184 |
| Vimpat | None | 12 | $12,551 | $1,046 |
| Atropine Sulfate | None | 15 | $2,073 | $138 |
| Gabapentin | None | 77 | $2,020 | $26 |
| Pyridostigmine | None | 22 | $1,711 | $78 |
| Donepezil | None | 124 | $1,604 | $13 |
| Mycophenolate Mofetil | None | 23 | $1,516 | $66 |
| Prednisone | None | 80 | $859 | $11 |
| Hydrocodone-Acetaminophen | None | 21 | $783 | $37 |
| Glycopyrrolate | None | 20 | $696 | $35 |
| Pregabalin | None | 14 | $686 | $49 |
| Duloxetine | None | 21 | $615 | $29 |
| Baclofen | None | 20 | $424 | $21 |
| Amitriptyline | None | 24 | $408 | $17 |
| Primidone | None | 18 | $309 | $17 |
| Escitalopram | None | 17 | $293 | $17 |
| Lidocaine-Prilocaine | None | 12 | $213 | $18 |
| Trazodone | None | 23 | $149 | $6 |
| Sertraline | None | 19 | $145 | $8 |
| Lorazepam | None | 11 | $95 | $9 |
| Zolpidem | None | 17 | $72 | $4 |
2020: 28 drugs
| Radicava | None | 111 | $1,284,970 | $11,576 |
| Acthar | None | 12 | $1,075,301 | $89,608 |
| Gammagard Liquid | Immune globulin | 34 | $327,734 | $9,639 |
| Privigen | Immune globulin | 12 | $287,886 | $23,990 |
| Gammaplex | Immune globulin | 29 | $281,032 | $9,691 |
| Gamunex-C | Immune globulin | 17 | $186,001 | $10,941 |
| Nuedexta | None | 41 | $61,706 | $1,505 |
| Riluzole | None | 148 | $31,977 | $216 |
| Azathioprine | None | 16 | $3,445 | $215 |
| Gabapentin | None | 106 | $3,306 | $31 |
| Memantine | None | 29 | $2,433 | $84 |
| Atropine Sulfate | None | 16 | $2,079 | $130 |
| Donepezil | None | 105 | $1,670 | $16 |
| Duloxetine | None | 18 | $1,476 | $82 |
| Baclofen | None | 29 | $1,205 | $42 |
| Hydrocodone-Acetaminophen | None | 31 | $1,073 | $35 |
| Glycopyrrolate | None | 15 | $926 | $62 |
| Prednisone | None | 77 | $838 | $11 |
| Mycophenolate Mofetil | None | 16 | $769 | $48 |
| Escitalopram | None | 43 | $710 | $17 |
| Amitriptyline | None | 28 | $579 | $21 |
| Tizanidine | None | 11 | $273 | $25 |
| Alprazolam | None | 11 | $259 | $24 |
| Lorazepam | None | 18 | $200 | $11 |
| Trazodone | None | 22 | $180 | $8 |
| Divalproex | None | 11 | $159 | $14 |
| Zolpidem | None | 22 | $114 | $5 |
| Sertraline | None | 20 | $82 | $4 |
2019: 17 drugs
| Radicava | None | 98 | $1,110,084 | $11,327 |
| Gammagard Liquid | Immune globulin | 47 | $551,156 | $11,727 |
| Nuedexta | None | 32 | $41,265 | $1,290 |
| Riluzole | None | 123 | $33,820 | $275 |
| Azathioprine | None | 25 | $2,915 | $117 |
| Gabapentin | None | 68 | $2,315 | $34 |
| Amitriptyline | None | 57 | $1,066 | $19 |
| Glycopyrrolate | None | 15 | $901 | $60 |
| Baclofen | None | 33 | $769 | $23 |
| Hydrocodone-Acetaminophen | None | 27 | $718 | $27 |
| Donepezil | None | 23 | $522 | $23 |
| Prednisone | None | 56 | $516 | $9 |
| Duloxetine | None | 17 | $409 | $24 |
| Clonazepam | None | 13 | $358 | $28 |
| Escitalopram | None | 25 | $219 | $9 |
| Sertraline | None | 25 | $103 | $4 |
| Zolpidem | None | 23 | $103 | $4 |
2018: 19 drugs
| Radicava | None | 94 | $1,041,609 | $11,081 |
| Privigen | Immune globulin | 33 | $378,598 | $11,473 |
| Gammagard Liquid | Immune globulin | 30 | $333,893 | $11,130 |
| Riluzole | None | 148 | $57,424 | $388 |
| Nuedexta | None | 26 | $34,876 | $1,341 |
| Gabapentin | None | 97 | $2,963 | $31 |
| Azathioprine | None | 36 | $2,729 | $76 |
| Pyridostigmine | None | 13 | $2,461 | $189 |
| Mexiletine | None | 16 | $2,242 | $140 |
| Baclofen | None | 23 | $769 | $33 |
| Hydrocodone-Acetaminophen | None | 36 | $767 | $21 |
| Glycopyrrolate | None | 11 | $714 | $65 |
| Amitriptyline | None | 27 | $658 | $24 |
| Clonazepam | None | 19 | $400 | $21 |
| Prednisone | None | 50 | $393 | $8 |
| Zolpidem | None | 24 | $263 | $11 |
| Lorazepam | None | 11 | $95 | $9 |
| Escitalopram | None | 13 | $87 | $7 |
| Citalopram Hbr | None | 11 | $47 | $4 |
2017: 21 drugs
| H.P. Acthar | None | 11 | $835,493 | $75,954 |
| Gammagard Liquid | Immune globulin | 35 | $429,889 | $12,283 |
| Privigen | Immune globulin | 21 | $415,421 | $19,782 |
| Radicava | None | 15 | $189,449 | $12,630 |
| Riluzole | None | 155 | $63,727 | $411 |
| Nuedexta | None | 54 | $41,663 | $772 |
| Gabapentin | None | 110 | $4,306 | $39 |
| Pyridostigmine | None | 16 | $3,401 | $213 |
| Azathioprine | None | 44 | $2,936 | $67 |
| Mexiletine | None | 18 | $1,863 | $103 |
| Carbamazepine | None | 16 | $1,145 | $72 |
| Amitriptyline | None | 49 | $1,086 | $22 |
| Prednisone | None | 47 | $590 | $13 |
| Duloxetine | None | 19 | $518 | $27 |
| Hydrocodone-Acetaminophen | None | 28 | $436 | $16 |
| Baclofen | None | 14 | $253 | $18 |
| Zolpidem | None | 38 | $231 | $6 |
| Escitalopram | None | 20 | $125 | $6 |
| Lorazepam | None | 14 | $109 | $8 |
| Trazodone | None | 13 | $99 | $8 |
| Tramadol | None | 17 | $42 | $2 |
2016: 23 drugs
| Privigen | Immune globulin | 13 | $376,532 | $28,964 |
| Gammagard Liquid | Immune globulin | 26 | $317,734 | $12,221 |
| Tecfidera | None | 13 | $82,698 | $6,361 |
| Riluzole | None | 143 | $28,486 | $199 |
| Nuedexta | None | 38 | $27,182 | $715 |
| Gabapentin | None | 121 | $6,521 | $54 |
| Savella | None | 12 | $3,870 | $322 |
| Pyridostigmine | None | 23 | $2,665 | $116 |
| Azathioprine | None | 30 | $1,362 | $45 |
| Baclofen | None | 30 | $789 | $26 |
| Methylprednisolone Sod Succ | None | 11 | $786 | $71 |
| Hydrocodone-Acetaminophen | None | 27 | $768 | $28 |
| Prednisone | None | 53 | $594 | $11 |
| Duloxetine | None | 14 | $586 | $42 |
| Escitalopram | None | 31 | $576 | $19 |
| Amitriptyline | None | 55 | $518 | $9 |
| Pramipexole Dihydrochloride | None | 19 | $361 | $19 |
| Mexiletine | None | 11 | $358 | $33 |
| Tramadol | None | 19 | $346 | $18 |
| Metoprolol | None | 11 | $207 | $19 |
| Zolpidem | None | 29 | $179 | $6 |
| Trazodone | None | 11 | $106 | $10 |
| Lorazepam | None | 11 | $68 | $6 |
2015: 21 drugs
| Gammagard Liquid | Immune globulin | 25 | $360,551 | $14,422 |
| Tecfidera | None | 12 | $68,250 | $5,687 |
| Riluzole | None | 103 | $30,757 | $299 |
| Lyrica | None | 22 | $7,654 | $348 |
| Gabapentin | None | 119 | $6,333 | $53 |
| Pyridostigmine | None | 15 | $2,040 | $136 |
| Azathioprine | None | 33 | $1,999 | $61 |
| Mexiletine | None | 21 | $1,385 | $66 |
| Carbidopa-Levodopa Er | None | 13 | $1,292 | $99 |
| Duloxetine | None | 18 | $1,275 | $71 |
| Amitriptyline | None | 81 | $1,057 | $13 |
| Pramipexole Dihydrochloride | None | 17 | $741 | $44 |
| Baclofen | None | 38 | $730 | $19 |
| Escitalopram | None | 40 | $709 | $18 |
| Dextroamphetamine-Amphetamine | None | 11 | $561 | $51 |
| Hydrocodone-Acetaminophen | None | 20 | $549 | $27 |
| Prednisone | None | 37 | $469 | $13 |
| Zolpidem | None | 25 | $336 | $13 |
| Tramadol | None | 18 | $271 | $15 |
| Alprazolam | None | 11 | $165 | $15 |
| Lorazepam | None | 21 | $115 | $5 |
2014: 18 drugs
| Gammagard Liquid | Immune globulin | 23 | $293,886 | $12,778 |
| Riluzole | None | 93 | $37,178 | $400 |
| Duloxetine | None | 26 | $6,956 | $268 |
| Lyrica | None | 19 | $5,538 | $291 |
| Gabapentin | None | 137 | $4,894 | $36 |
| Savella | None | 11 | $2,094 | $190 |
| Carbidopa-Levodopa Er | None | 20 | $1,434 | $72 |
| Escitalopram | None | 44 | $1,014 | $23 |
| Pyridostigmine | None | 13 | $886 | $68 |
| Azathioprine | None | 24 | $846 | $35 |
| Amitriptyline | None | 75 | $805 | $11 |
| Pramipexole Dihydrochloride | None | 38 | $607 | $16 |
| Mexiletine | None | 21 | $596 | $28 |
| Amphetamine Salt Combo | None | 11 | $579 | $53 |
| Hydrocodone-Acetaminophen | None | 19 | $420 | $22 |
| Baclofen | None | 24 | $368 | $15 |
| Prednisone | None | 27 | $326 | $12 |
| Mirtazapine | None | 19 | $141 | $7 |
2013: 17 drugs
| Gammagard Liquid | Immune globulin | 35 | $433,126 | $12,375 |
| Rilutek | None | 63 | $119,803 | $1,902 |
| Riluzole | None | 28 | $21,605 | $772 |
| Lyrica | None | 31 | $6,960 | $225 |
| Cymbalta | None | 23 | $5,364 | $233 |
| Methylprednisolone Sod Succ | None | 33 | $1,361 | $41 |
| Gabapentin | None | 51 | $1,337 | $26 |
| Escitalopram | None | 50 | $1,299 | $26 |
| Carbidopa-Levodopa Er | None | 11 | $938 | $85 |
| Carbidopa-Levodopa | None | 17 | $542 | $32 |
| Amitriptyline | None | 40 | $382 | $10 |
| Pramipexole Dihydrochloride | None | 30 | $335 | $11 |
| Hydrocodone-Acetaminophen | None | 20 | $253 | $13 |
| Sertraline | None | 13 | $181 | $14 |
| Prednisone | None | 22 | $165 | $8 |
| Zolpidem | None | 13 | $105 | $8 |
| Fluoxetine | None | 12 | $68 | $6 |
Money from drug and device companies
$56,097 in 2025
| 2025 | 13 | 34 | $52,598 | $56,097 |
| 2024 | 9 | 66 | $51,445 | $63,305 |
| 2023 | 10 | 42 | $13,436 | $16,437 |
| 2022 | 10 | 43 | $39,393 | $49,401 |
| 2021 | 8 | 9 | $23,658 | $23,722 |
| 2020 | 8 | 35 | $23,165 | $26,096 |
| 2019 | 12 | 122 | $44,645 | $58,680 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Janssen Research & Development | None | $16,200 | 1 payment
|
| Grifols USA | Gamunex-C | $12,748 | 10 payments
|
| Novavax | Novavax Covid-19 Vaccine, Adjuvanted | $10,500 | 1 payment
|
| Genzyme | None | $10,360 | 1 payment
|
| Amgen | Uplizna | $3,513 | 3 payments
|
| Grifols Shared Services North America | Gamunex-C | $2,100 | 1 payment
|
See all 34 published payments
| Biogen | Meals · 2025-12-18 | Qalsody | $27 |
| Amgen | Consulting · 2025-12-16 | Uplizna | $1,925 |
| Alnylam Pharmaceuticals | Meals · 2025-12-15 | Amvuttra | $26 |
| Grifols USA | Travel · 2025-11-22 | Gamunex-C | $744 |
| Grifols USA | Travel · 2025-11-22 | Gamunex-C | $1,352 |
| Grifols USA | Consulting · 2025-11-22 | Gamunex-C | $10,000 |
| Grifols USA | Travel · 2025-11-22 | Gamunex-C | $212 |
| Grifols USA | Meals · 2025-11-22 | Gamunex-C | $333 |
| Amgen | Consulting · 2025-11-11 | Uplizna | $1,513 |
| Amgen | Meals · 2025-10-28 | Uplizna | $75 |
| Grifols USA | Meals · 2025-10-16 | Gamunex-C | $27 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-08 | Wainua | $17 |
| Tanabe Pharma America | Meals · 2025-08-21 | Radicava | $23 |
| Grifols Shared Services North America | Consulting · 2025-07-25 | Gamunex-C | $2,100 |
| Alexion Pharmaceuticals | Meals · 2025-07-17 | Ultomiris | $34 |
| Grifols USA | Meals · 2025-06-19 | Gamunex-C | $28 |
| Janssen Research & Development | Consulting · 2025-06-02 | None | $16,200 |
| Genzyme | Consulting · 2025-05-30 | None | $10,360 |
| Pfizer | Meals · 2025-05-18 | None | $89 |
| Argenx US | Travel · 2025-05-16 | Vyvgart Hytrulo | $83 |
| Argenx US | Travel · 2025-05-16 | Vyvgart Hytrulo | $58 |
| Argenx US | Travel · 2025-05-16 | Vyvgart Hytrulo | $31 |
| Argenx US | Travel · 2025-05-16 | Vyvgart Hytrulo | $23 |
| Tanabe Pharma America | Meals · 2025-05-06 | Radicava | $15 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-04-18 | Wainua | $23 |
| Argenx US | Meals · 2025-04-04 | Vyvgart Hytrulo | $87 |
| Argenx US | Meals · 2025-04-04 | Vyvgart Hytrulo | $20 |
| Argenx US | Meals · 2025-04-04 | Vyvgart Hytrulo | $20 |
| Argenx US | Meals · 2025-04-04 | Vyvgart Hytrulo | $75 |
| Grifols USA | Meals · 2025-03-20 | Gamunex-C | $2 |
| Grifols USA | Meals · 2025-03-19 | Gamunex-C | $25 |
| Tanabe Pharma America | Meals · 2025-02-20 | Radicava | $26 |
| Grifols USA | Meals · 2025-01-30 | Gamunex-C | $24 |
| Novavax | Consulting · 2025-01-16 | Novavax Covid-19 Vaccine, Adjuvanted | $10,500 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $63,305
| Grifols USA | Gamunex-C | $34,082 | 14 payments
|
| Janssen Research & Development | None | $10,200 | 1 payment
|
| Argenx US | Vyvgart | $7,184 | 8 payments
|
| Mitsubishi Tanabe Pharma America | Radicava Ors | $6,130 | 12 payments
|
| Johnson & Johnson Health Care Systems | None | $5,358 | 3 payments
|
| Alexion Pharmaceuticals | Ultomiris | $129 | 4 payments
|
| Biogen | Spinraza | $94 | 4 payments
|
| Alnylam Pharmaceuticals | Amvuttra | $87 | 3 payments
|
| Grifols Shared Services North America | Gamunex-C | $41 | 2 payments
|
2023: $16,437
| Grifols USA | Gamunex-C | $9,676 | 12 payments
|
| Janssen Research & Development | None | $3,000 | 1 payment
|
| Argenx US | Vyvgart | $2,266 | 4 payments
|
| PTC Therapeutics | None | $928 | 2 payments
|
| Amylyx Pharmaceuticals | Relyvrio | $300 | 5 payments
|
| Mitsubishi Tanabe Pharma America | Radicava | $84 | 3 payments
|
| Biogen | Spinraza | $62 | 2 payments
|
| Alnylam Pharmaceuticals | Amvuttra | $46 | 2 payments
|
| Ucb | None | $43 | 1 payment
|
| Alexion Pharmaceuticals | Ultomiris | $32 | 1 payment
|
2022: $49,401
| Grifols USA | Gamunex-C | $27,576 | 12 payments
|
| Biogen | Spinraza | $8,456 | 5 payments
|
| Ucb | None | $7,697 | 10 payments
|
| Mitsubishi Tanabe Pharma America | Radicava | $2,326 | 3 payments
|
| Alexion Pharmaceuticals | Soliris | $2,065 | 2 payments
|
| Argenx US | None | $1,150 | 1 payment
|
| Alnylam Pharmaceuticals | Onpattro | $41 | 2 payments
|
| SK Life Science | None | $34 | 1 payment
|
| Baxter Healthcare | Hillrom - Vest System Model 105 Home Care | $30 | 1 payment
|
| PTC Therapeutics | None | $28 | 1 payment
|
2021: $23,722
| Grifols USA | Gamunex-C | $16,000 | 1 payment
|
| Biogen | None | $3,390 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | None | $1,600 | 1 payment
|
| Pfizer | Octagam Immune Globulin (Human) | $1,480 | 1 payment
|
| Alexion Pharmaceuticals | None | $638 | 1 payment
|
| Mitsubishi Tanabe Pharma America | Radicava | $550 | 1 payment
|
| Teva Pharmaceuticals USA | Ajovy | $42 | 2 payments
|
| SK Life Science | None | $22 | 1 payment
|
2020: $26,096
| Grifols USA | Gamunex-C | $11,400 | 7 payments
|
| Alexion Pharmaceuticals | Soliris | $8,244 | 6 payments
|
| Mitsubishi Tanabe Pharma America | Radicava | $3,300 | 3 payments
|
| CSL Behring | Hizentra | $1,645 | 1 payment
|
| Mitsubishi Tanabe Pharma Development America | None | $1,413 | 9 payments
|
| Biogen | Spinraza | $59 | 1 payment
|
| Upsher-Smith Laboratories | Tosymra Sumatriptan Nasal Spray | $19 | 1 payment
|
| Alnylam Pharmaceuticals | Onpattro | $18 | 1 payment
|
2019: $58,680
| Mitsubishi Tanabe Pharma America | Radicava | $22,722 | 43 payments
|
| Alexion Pharmaceuticals | Soliris | $14,292 | 29 payments
|
| Grifols USA | Gamunex-C | $11,772 | 9 payments
|
| Shire North American Group | Gammagard Liquid | $3,689 | 4 payments
|
| CSL Behring | Hizentra | $3,089 | 6 payments
|
| Biogen | Spinraza | $2,307 | 4 payments
|
| EDW Pharma | Tiglutik | $483 | 1 payment
|
| Akcea Therapeutics | Tegsedi | $149 | 2 payments
|
| Avanir Pharmaceuticals | Nuedexta | $68 | 3 payments
|
| Genzyme | Lumizyme | $50 | 2 payments
|
| Pfizer | None | $41 | 1 payment
|
| Alnylam Pharmaceuticals | Onpattro | $18 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Biogen, Inc. · An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Biib067 in Adults With Inherited Amyotrophic Lateral Sclerosis (Als) · 2020 | Their institution | $118,532 |
| GENZYME CORPORATION · A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Sar443820 in Adult Participants With Amyotrophic Lateral Sclerosis, Followed By An Open-Label Extension · 2023 | Their institution | $107,160 |
| Genentech, Inc. · Ph 1a Sad of Gdc 0134 in Als Patients · 2020 | Their institution | $93,687 |
| Biogen, Inc. · Long-Term Evaluation of Biib067 · 2020 | Their institution | $87,835 |
| Genentech, Inc. · Ph 1a Sad of Gdc 0134 in Als Patients · 2019 | Their institution | $66,616 |
| Biogen, Inc. · Long-Term Evaluation of Biib067 · 2021 | Their institution | $56,234 |
| Biogen, Inc. · An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Biib067 in Adults With Inherited Amyotrophic Lateral Sclerosis (Als) · 2021 | Their institution | $52,147 |
| Biogen, Inc. · An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Biib067 in Adults With Inherited Amyotrophic Lateral Sclerosis (Als) · 2019 | Their institution | $46,729 |
| Biohaven Pharmaceutical Holding Company Ltd. · Healey Platform Trial · 2022 | Their institution | $44,000 |
| PTC Therapeutics, Inc. · A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Study To Assess the Efficacy, Safety, Tolerability, Pk, and Biomarker Effects of Ptc857 in Adult Subjects With Amyotrophic Lateral Sclerosis (Cardinals) · 2023 | Their institution | $40,687 |
| PTC Therapeutics, Inc. · A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Study To Assess the Efficacy, Safety, Tolerability, Pk, and Biomarker Effects Ofptc857in Adult Subjects Withamyotrophic Lateral Sclerosis(Cardinals) · 2025 | Their institution | $38,370 |
| UCB SA · Phase 3, Multicenter, Randomized, Double-Blind, Pbo-Controlled Study of Efficacy, Safety, and Tolerability of Zilucoplan in Subjects With Generalized Myasthenia Gravis · 2021 | Their institution | $31,695 |
| PTC Therapeutics, Inc. · A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Study To Assess the Efficacy, Safety, Tolerability, Pk, and Biomarker Effects Ofptc857in Adult Subjects Withamyotrophic Lateral Sclerosis(Cardinals) · 2024 | Their institution | $30,392 |
| ABBVIE INC. · A Phase 1 Study To Investigate the Safety and Pharmacokinetics of Abbv-Cls-7262 in Patients With Amyotrophic Lateral Sclerosis · 2025 | Their institution | $29,615 |
| Amylyx Pharmaceuticals, Inc. · Phase III Trial of Amx0035 for Amyotrophic Lateral Sclerosis Treatment (Phoenix) · 2023 | Their institution | $28,799 |
| UCB SA · A Phase 3, Randomized, Doubl-Blind, Placebo-Controlled Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis · 2020 | Their institution | $27,835 |
| UCB SA · Phase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects With Generalized Myasthenia Gravis · 2021 | Their institution | $26,487 |
| UCB SA · The Healey Platform Trial · 2021 | Their institution | $26,072 |
| UCB SA · The Healy Platform Trial · 2021 | Their institution | $26,072 |
| Biogen, Inc. · A Phase 3 Randomized, Placebo-Controlled Trial of Tofersen in Adults With A Confirmed Mutation in the Superoxide Dismutase 1 Mutation Gene Who Are Clinically Presymptomatic for Amyotrophic Lateral Sclerosis With A Longitudinal Natural History Run-in and Open-Label Extension · 2022 | Their institution | $23,572 |
| Alexion Pharmaceuticals, Inc. · A Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study To Evaluate the Efficacy and Safety of Alxn2050 in Adult Participants With Generalized Myasthe · 2024 | Their institution | $20,900 |
| Biogen, Inc. · A Phase 3 Randomized, Placebo-Controlled Trial of Tofersen in Adults With A Confirmed Mutation in the Superoxide Dismutase 1 Mutation Gene Who Are Clinically Presymptomatic for Amyotrophic Lateral Sclerosis With A Longitudinal Natural History Run-in and Open-Label Extension · 2024 | Their institution | $20,264 |
| UCB SA · Phase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects With Generalized Myasthenia Gravis · 2025 | Their institution | $19,982 |
| UCB SA · The Healey Platform Trial · 2022 | Their institution | $17,929 |
| Alexion Pharmaceuticals, Inc. · An Extension Trial of Ecu-Mg-301 To Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis · 2019 | Their institution | $16,756 |
| GENZYME CORPORATION · A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Sar443820 in Adult Participants With Amyotrophic Lateral Sclerosis, Followed By An Open-Label Extension · 2022 | Their institution | $16,700 |
| UCB SA · A Randomized, Open Label Extension Study To Investigate the Long-Term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis · 2020 | Their institution | $16,292 |
| ARGENX US, INC. · A Phase 2 Trial To Investigate the Efficacy, Safety, and Tolerability of Subcutaneously Administered Efgartigimod With Rhuph20 in Adult Patients With Chronic Inflammatory Demyelinating Polyneuropathy (Cidp) · 2023 | Their institution | $16,217 |
| UCB SA · Phase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects With Generalized Myasthenia Gravis · 2023 | Their institution | $15,927 |
| Orion Corporation · Effects of Oral Levosimendan (Odm-109) on Respiratory Function in Patients With Als · 2020 | Their institution | $15,492 |
| Biogen, Inc. · A Phase 3 Randomized, Placebo-Controlled Trial of Tofersen in Adults With A Confirmed Mutation in the Superoxide Dismutase 1 Mutation Gene Who Are Clinically Presymptomatic for Amyotrophic Lateral Sclerosis With A Longitudinal Natural History Run-in and Open-Label Extension · 2023 | Their institution | $15,468 |
| Biogen, Inc. · Methodology Study of Novel Outcome Measures To Assess Progression of Als · 2019 | Their institution | $15,313 |
| Orion Corporation · Effects of Oral Levosimendan (Odm-109) on Respiratory Function in Patients With Als · 2019 | Their institution | $15,041 |
| Biogen, Inc. · A Phase 3 Randomized, Placebo-Controlled Trial of Tofersen in Adults With A Confirmed Mutation in the Superoxide Dismutase 1 Mutation Gene Who Are Clinically Presymptomatic for Amyotrophic Lateral Sclerosis With A Longitudinal Natural History Run-in and Open-Label Extension · 2021 | Their institution | $13,650 |
| GENZYME CORPORATION · A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Sar443820 in Adult Participants With Amyotrophic Lateral Sclerosis, Followed By An Open-Label Extension · 2024 | Their institution | $13,525 |
| ARGENX US, INC. · Open-Label Extension of the Argx-113-1802 Trial To Investigate the Long-Term Safety, Tolerability, and Efficacy of Efgartigimod Ph20 Sc in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (Cidp) · 2022 | Their institution | $12,400 |
| MITSUBISHI TANABE PHARMA DEVELOPMENT AMERICA, INC. · Safety Study of Oral Edaravone Administered in Subjects With Als · 2020 | Their institution | $11,800 |
| Alexion Pharmaceuticals, Inc. · A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Nave Adult Patients With Generalized Myasthenia Gravis · 2021 | Their institution | $10,561 |
| AbbVie Inc. · A Phase 1 Study To Investigate the Safety and Pharmacokinetics of Abbv-Cls-7262 in Patients With Amyotrophic Lateral Sclerosis · 2024 | Their institution | $10,232 |
| Biogen, Inc. · A Phase 1 Placebo-Controlled, Single and Multiple Ascending Dose Study To Evaluate the Safety, Tolerability, and Pharmacokinetics of Biib067 Administered To Adult Subjects With Amyotrophic Lateral Sclerosis. · 2022 | Their institution | $9,338 |
| Biogen, Inc. · A Phase 3 Randomized, Placebo-Controlled Trial of Tofersen in Adults With A Confirmed Mutation in the Superoxide Dismutase 1 Mutation Gene Who Are Clinically Presymptomatic for Amyotrophic Lateral Sclerosis With A Longitudinal Natural History Run-in and Open-Label Extension · 2025 | Their institution | $8,671 |
| ARGENX US, INC. · Open-Label Extension of the Argx-113-1802 Trial To Investigate the Long-Term Safety, Tolerability, and Efficacy of Efgartigimod Ph20 Sc in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (Cidp) · 2025 | Their institution | $7,100 |
| UCB SA · Phase 3, Multicenter, Randomized, Double-Blind, Pbo-Controlled Study of Efficacy, Safety, and Tolerability of Zilucoplan in Subjects With Generalized Myasthenia Gravis · 2023 | Their institution | $5,800 |
| UCB SA · Phase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects With Generalized Myasthenia Gravis · 2022 | Their institution | $5,739 |
| Biogen, Inc. · An Extension Study To Assess the Long-Term Safety, Tolerability, Pharmacokinetics, and Effect of Disease Progression of Biib067 Administered To Previously Treated Adults With Amyotrophic Lateral Sclerosis Caused By Superoxide Dismutase 1 Mutation · 2022 | Their institution | $5,627 |
| Mallinckrodt Hospital Products Inc. · A Double Blind, Placebo Controlled Study of H.P. Acthar Gel in the Management of Amyotrophic Lateral Sclerosis · 2020 | Their institution | $5,050 |
| UCB SA · A Phase 3, Randomized, Doubl-Blind, Placebo-Controlled Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis · 2021 | Their institution | $4,095 |
| Alexion Pharmaceuticals, Inc. · A Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study To Evaluate the Efficacy and Safety of Alxn2050 in Adult Participants With Generalized Myasthe · 2022 | Their institution | $3,750 |
| MITSUBISHI TANABE PHARMA DEVELOPMENT AMERICA, INC. · Safety Study of Oral Edaravone Administered in Subjects With Als · 2021 | Their institution | $3,450 |
| UCB SA · Phase 3, Multicenter, Randomized, Double-Blind, Pbo-Controlled Study of Efficacy, Safety, and Tolerability of Zilucoplan in Subjects With Generalized Myasthenia Gravis · 2022 | Their institution | $3,390 |
| Biogen, Inc. · An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Biib067 in Adults With Inherited Amyotrophic Lateral Sclerosis (Als) · 2019 | This clinician | $2,797 |
| Alexion Pharmaceuticals, Inc. · A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study With An Open-Label Extension To Evaluate the Efficacy and Safety of Ravulizumab in Patients With Amyotrophic Lateral Sclerosis (Als) · 2021 | Their institution | $2,035 |
| Biogen, Inc. · Methodology Study of Novel Electrophysiological, Physical, and Imaging Outcome Measures To Assess the Progression of Amyotrophic Lateral Sclerosis · 2022 | Their institution | $1,974 |
| UCB SA · A Randomized, Open Label Extension Study To Investigate the Long-Term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis · 2021 | Their institution | $1,485 |
| Alexion Pharmaceuticals, Inc. · A Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study To Evaluate the Efficacy and Safety of Alxn2050 in Adult Participants With Generalized Myasthe · 2023 | Their institution | $1,000 |
| ARGENX US, INC. · Open-Label Extension of the Argx-113-1802 Trial To Investigate the Long-Term Safety, Tolerability, and Efficacy of Subcutaneously Administered Efgartigimod With Rhuph20 in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (Cidp) · 2023 | Their institution | $800 |
| UCB SA · Phase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects With Generalized Myasthenia Gravis · 2024 | Their institution | $652 |
| Alexion Pharmaceuticals, Inc. · Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis · 2020 | Their institution | $573 |
| UCB Biosciences Inc. · Phase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects With Generalized Myasthenia Gravis · 2022 | Their institution | $563 |
| Biogen, Inc. · Methodology Study of Novel Outcome Measures To Assess Progression of Als · 2020 | Their institution | $458 |
| UCB SA · A Phase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects With Generalized Myasthenia Gravis · 2023 | Their institution | $176 |
Professional record
- NPI
- 1457372823
- Licence
- CA A54410California A54410: Current · expires 2027-05-31
- Trained
- Tulane University School of Medicine, 1988
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Neurology (2084N0400X); Federal specialty code 207ZP0102X (207ZP0102X)
- Mailing address
- 2350 W El Camino Real Fl 2, Mountain View, CA, 94040
- NPI first listed
- 2006-07-21
- NPI last updated
- 2023-03-07
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 165 Rowland Way Ste 201, Novato, CA, 94945 · 1315 Alhambra Blvd Ste 210, Sacramento, CA, 95816 · 1580 Valencia St Ste 106, San Francisco, CA, 94110